Astrana Health, Inc.
Bear Case (25th pct.)
-56.2% vs price
Base Case (Median)
-42.4% vs price
Bull Case (75th pct.)
-20.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $33.06 | -16.8% | High (40%) |
| PE Comparable | $18.25 | -54.1% | Medium (25%) |
| Graham Number | $17.12 | -56.9% | Medium (40%) |
| EV/EBITDA | $27.57 | -30.7% | Medium (20%) |
| EV/FCF | $64.57 | 62.4% | Medium (20%) |
| Earnings Power Value | $5.94 | -85.0% | Medium (50%) |
Based on 6 out of 8 methods, ASTH appears overvalued at the current price of $39.75. The base case fair value of $22.91 implies 42.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.